Who invested in Biolex Therapeutics?
Biolex Therapeutics's investors include Johnson & Johnson Development Corporation (JJDC), Intersouth Partners, Quaker Partners, Mitsui Ventures and Polaris Partners, and 16 more on record.
United States · Funded startup
9 rounds we have observed, with the 21 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.
Funding summaryUpdated 26 Oct 2026
$197Mraised across 9 rounds since 2003, from 9 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
No investor was named in the report.
Reported by sec.govSEC filing: $2.4M sold, first sale Dec 2011
No investor was named in the report.
Reported by sec.govSEC filing: $5.9M sold, first sale May 2011
No investor was named in the report.
Reported by fis.dowjones.comSEC filing: $8.7M sold, first sale Jul 2010
No investor was named in the report.
From a historical funding recordSEC filing: $10M sold, first sale Feb 2010
Reported by biolex.com
From a historical funding record
From a historical funding record
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Biolex Therapeutics's investors include Johnson & Johnson Development Corporation (JJDC), Intersouth Partners, Quaker Partners, Mitsui Ventures and Polaris Partners, and 16 more on record.
Biolex Therapeutics has raised $197M across 9 rounds since 2003.
Biolex Therapeutics's most recent round was a Debt of $2.4M in Dec 2011.
Biolex Therapeutics's largest round on record is $60M (Series D), in Oct 2008.
Biolex Therapeutics's first round on record, in Aug 2003, was backed by Intersouth Partners, Johnson & Johnson Development Corporation (JJDC) and Quaker Partners and 9 others.
Biolex Therapeutics's latest named round is a Debt, in Dec 2011.
Biolex Therapeutics is based in the United States.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.